Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

NCT06534437 is registered in ClinicalTrials.gov with Ryvu Therapeutics SA as lead sponsor.

NCT NCT06534437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06534437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Lead sponsor
Ryvu Therapeutics SA
Phase
Phase 2
Overall status
Recruiting
Start date
December 5, 2024
Completion date
December 31, 2026
Enrollment
178 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma, b-cell